SPRB
Spruce Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$57.78
+0.12%Aug 26, 2026, 12:00 UTC
Spruce Biosciences launched MPS3BStudy.com, an online resource for families and caregivers of children with Sanfilippo Syndrome Type B (MPS IIIB), enabling them to learn about and register interest in a related study.
Source:Aug 21, 2026, 13:51 UTC
Spruce Biosciences hired Adrian Quartel as chief medical officer.
Source:Aug 12, 2026, 12:00 UTC
Cure Sanfilippo Foundation and the National MPS Society agreed to make a combined $5.5 million strategic investment in Spruce Biosciences.
Source:Aug 12, 2026, 00:00 UTC
Spruce Biosciences reported Q2 2026 results with a net loss of $16.2 million and diluted EPS of -$6.68, and cash and cash equivalents of $96.3 million as of June 30, 2026.
Jul 27, 2026, 00:00 UTC
Spruce Biosciences appointed Adrian Quartel as Chief Medical Officer, effective July 27, 2026, succeeding Kirk Ways who stepped down as Interim Chief Medical Officer on the same date.